MX388963B - Formulacion farmaceutica acuosa de tapentadol para administracion oral - Google Patents

Formulacion farmaceutica acuosa de tapentadol para administracion oral

Info

Publication number
MX388963B
MX388963B MX2017013504A MX2017013504A MX388963B MX 388963 B MX388963 B MX 388963B MX 2017013504 A MX2017013504 A MX 2017013504A MX 2017013504 A MX2017013504 A MX 2017013504A MX 388963 B MX388963 B MX 388963B
Authority
MX
Mexico
Prior art keywords
oral administration
tapentadol
aqueous pharmaceutical
pharmaceutical formulation
relying
Prior art date
Application number
MX2017013504A
Other languages
English (en)
Inventor
Augusta Carolus Roger Embrechts
Eva Wulsten
Katrien Karine Sabine Inghelbrecht
Marc Schiller
Ulrich Feil
Ulrich Reinhold
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44650617&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX388963(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX388963B publication Critical patent/MX388963B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a una composición farmacéutica acuosa que contiene tapentadol o una sal fisiológicamente aceptable del mismo y que está adaptada para ser administrable por vía oral. La composición tiene una excelente estabilidad de almacenamiento sin depender de la presencia de altas cantidades de conservadores.
MX2017013504A 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral MX388963B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449287P 2011-03-04 2011-03-04
EP11003601 2011-05-03
PCT/EP2012/000904 WO2012119727A1 (en) 2011-03-04 2012-03-02 Aqueous pharmaceutical formulation of tapentadol for oral administration

Publications (1)

Publication Number Publication Date
MX388963B true MX388963B (es) 2025-03-20

Family

ID=44650617

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2017007718A MX369121B (es) 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MX2017013504A MX388963B (es) 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral
MX2013010101A MX351584B (es) 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017007718A MX369121B (es) 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2013010101A MX351584B (es) 2011-03-04 2012-03-02 Formulacion farmaceutica acuosa de tapentadol para administracion oral.

Country Status (23)

Country Link
US (3) US20130022670A1 (es)
EP (4) EP3685827A1 (es)
JP (3) JP6046057B2 (es)
KR (2) KR101946790B1 (es)
CN (2) CN107308108A (es)
AU (2) AU2012224952C1 (es)
BR (1) BR112013022495A2 (es)
CA (1) CA2828631C (es)
CY (2) CY1125100T1 (es)
DK (2) DK3287123T3 (es)
EA (2) EA027290B1 (es)
ES (1) ES2756776T3 (es)
HR (2) HRP20191777T1 (es)
HU (1) HUE046557T2 (es)
IL (2) IL227824B (es)
LT (2) LT2680832T (es)
MX (3) MX369121B (es)
PL (2) PL3287123T3 (es)
PT (2) PT2680832T (es)
RS (2) RS60267B1 (es)
SI (2) SI3287123T1 (es)
WO (1) WO2012119727A1 (es)
ZA (1) ZA201306478B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
MX2010012039A (es) 2008-05-09 2010-11-30 Gruenenthal Gmbh Proceso para la preparacion de una formulacion de polvo intermedia y una forma de dosificacion solida final bajo el uso de un paso de congelacion por rocio.
ES2428938T3 (es) 2009-07-22 2013-11-12 Grünenthal GmbH Forma de dosificación resistente a la manipulación y estabilizada frente a la oxidación
BR112012001547A2 (pt) 2009-07-22 2016-03-08 Gruenenthal Gmbh forma de dosagem farmacêutica extrusada por fusão a quente
CN103179954A (zh) 2010-09-02 2013-06-26 格吕伦塔尔有限公司 包含阴离子聚合物的抗破碎剂型
CA2808219C (en) 2010-09-02 2019-05-14 Gruenenthal Gmbh Tamper resistant dosage form comprising inorganic salt
MX369121B (es) 2011-03-04 2019-10-30 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
US11413239B2 (en) 2011-07-20 2022-08-16 Torrent Pharmaceuticals Ltd. Pharmaceutical composition of tapentadol for nasal administration
CA2839123A1 (en) 2011-07-29 2013-02-07 Grunenthal Gmbh Tamper-resistant tablet providing immediate drug release
PL2736497T3 (pl) 2011-07-29 2018-01-31 Gruenenthal Gmbh Tabletka odporna na ingerencję, zapewniająca natychmiastowe uwalnianie leku
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
PL2838512T3 (pl) 2012-04-18 2018-12-31 Grünenthal GmbH Farmaceutyczna postać dawkowania odporna na niewłaściwe użycie i odporna na uderzeniowe uwalnianie dawki
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014191396A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP2845625A1 (en) 2013-09-04 2015-03-11 Grünenthal GmbH Tapentadol for use in the treatment of fibromyalgia and chronic fatigue syndrome
WO2015078891A1 (en) 2013-11-26 2015-06-04 Farmaceutici Formenti S.P.A. Preparation of a powdery pharmaceutical composition by means of cryo-milling
US20150320690A1 (en) 2014-05-12 2015-11-12 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EP3148512A1 (en) 2014-05-26 2017-04-05 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
EA036258B1 (ru) 2015-03-27 2020-10-20 Грюненталь Гмбх Стабильный препарат для парентерального введения тапентадола
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN105997862A (zh) * 2016-07-15 2016-10-12 蓝佳堂生物医药（福建）有限公司 一种口腔溃疡含漱液及其制备方法
CN109996533A (zh) 2016-09-23 2019-07-09 格吕伦塔尔有限公司 用于肠胃外施用他喷他多的稳定制剂
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
CN108434042A (zh) * 2018-05-31 2018-08-24 武汉新大地环保材料股份有限公司 一种新型日化防腐剂及其制备方法
EP4011369A1 (en) 2020-12-14 2022-06-15 G.L. Pharma GmbH Aqueous pharmaceutical composition comprising tapentadol tartrate

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334423D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
GB8334422D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
US4775678A (en) 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
CA2013755C (en) 1989-04-05 1993-11-30 Simon Benita Medicinal emulsions
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6211169B1 (en) 1999-09-29 2001-04-03 Aesgen, Inc. Stable calcitriol solution for packaging into vials
FR2809619B1 (fr) 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US6594193B2 (en) * 2000-06-22 2003-07-15 Progressent Technologies, Inc. Charge pump for negative differential resistance transistor
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
JP4905616B2 (ja) 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
FR2832063B1 (fr) 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
JP2005526079A (ja) * 2002-03-15 2005-09-02 サイプレス バイオサイエンス， インコーポレイテッド 内蔵痛症候群を処置するためのｎｅおよび５−ｈｔ再取り込み阻害剤
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040101563A1 (en) * 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
RU2359698C2 (ru) * 2002-09-13 2009-06-27 Сайдекс, Инк. Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
US6888993B2 (en) 2002-11-27 2005-05-03 Corning Incorporated Dispersion compensating optical fiber for SMF and transmission link including same
ITMI20022748A1 (it) 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
EP1599222B1 (en) 2003-01-08 2009-03-04 Novartis Vaccines and Diagnostics, Inc. Stabilized aqueous compositions comprising tissue factor pathway inhibitor (tfpi) or tissue factor pathway inhibitor variant
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
JP2007538091A (ja) * 2004-05-17 2007-12-27 ファーマコフォア・インコーポレイテッド 痛みを処置または予防するための組成物および方法
SI1612203T1 (sl) 2004-06-28 2007-12-31 Gruenenthal Chemie Kristalne oblike (-)-(1R,2R)-3-(3-dimetilamino-1-etil-2-metilpropil)-fenol hidroklorida
KR101204657B1 (ko) 2004-07-01 2012-11-27 그뤼넨탈 게엠베하 (1r,2r)-3-(3-디메틸아미노-1-에틸-2-메틸-프로필)-페놀을 함유하는 남용 방지 경구 투여 제형
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
US20110098284A1 (en) * 2005-04-28 2011-04-28 Najib Babul Methods and compositions for treating pain
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
WO2007070504A2 (en) * 2005-12-13 2007-06-21 Morton Grove Pharmaceuticals, Inc. Stable and palatable oral liquid sumatriptan compositions
US8176534B2 (en) 2005-12-30 2012-05-08 General Instrument Corporation Method and apparatus for provisioning a device to access digital rights management (DRM) services in a universal plug and play (UPnP) network
EP2010145A2 (en) 2006-04-25 2009-01-07 Croda, Inc. Modification of percutaneous absorption of topically active materials
WO2007128413A1 (en) 2006-04-28 2007-11-15 Grünenthal GmbH Pharmaceutical combination comprising 3- ( 3-dimethylamino-1-ethyl-2-methyl-propyl) -phenol and paracetamol
PL2012763T3 (pl) * 2006-04-28 2011-08-31 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylo-propylo)-fenol i NSAID
TWI401237B (zh) * 2006-07-24 2013-07-11 ３-〔（１ｒ，２ｒ）-３-（二甲基氨基）-１-乙基-２-甲基丙基〕酚之製備
KR101370398B1 (ko) 2006-07-24 2014-03-05 얀센 파마슈티카 엔.브이. (２ｒ,３ｒ)-３-(３-메톡시페닐)-ｎ,ｎ,２-트리메틸펜탄아민의 제조방법
EP1905440A1 (de) 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP1992334A1 (en) 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
CA2705422A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
CN102065852B (zh) * 2007-11-23 2015-06-17 格吕伦塔尔有限公司 他喷他多组合物
JP2011506342A (ja) 2007-12-06 2011-03-03 ペイン セラピューティクス インコーポレイテッド 微粉化オピオイド組成物、製剤および剤形、ならびにそれらの製造方法
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
WO2009124586A1 (en) 2008-04-08 2009-10-15 Arpida Ag Aqueous pharmaceutical formulation
NZ592437A (en) * 2008-10-30 2013-03-28 Gruenenthal Chemie A dosage form comprising tapentadol and an opioid antagonist
MX2011007399A (es) * 2009-01-09 2011-11-18 Panacea Biotec Ltd Suspension farmaceutica de liberacion doble.
WO2010100477A2 (en) * 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) * 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
AU2010281436B2 (en) 2009-07-27 2016-03-24 Tonix Pharma Limited. Methods for treatment of pain
WO2011016487A1 (ja) * 2009-08-05 2011-02-10 ナガセ医薬品株式会社 インジゴカルミン製剤
WO2011071400A1 (en) 2009-12-10 2011-06-16 Tecnimede - Sociedade Técnico-Medicinal, S.A. Method and composition for preparing stable liquid formulations of paracetamol
US20110190267A1 (en) 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
MX2012011355A (es) 2010-03-30 2012-11-30 Phosphagenics Ltd Parche de suministro transdermico.
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
CN101948397A (zh) * 2010-09-07 2011-01-19 天津泰普药品科技发展有限公司 镇痛药他喷他多重要中间体的制备方法
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
EA024193B1 (ru) 2011-03-04 2016-08-31 Грюненталь Гмбх Фармацевтическая композиция на водной основе, предназначенная для парентерального введения тапентадола
MX369121B (es) 2011-03-04 2019-10-30 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral.
MX374468B (es) 2011-03-04 2025-03-06 Gruenenthal Gmbh Composicion farmaceutica acuosa semisolida que contiene tapentadol.
US20150073000A1 (en) 2012-03-27 2015-03-12 Fresenius Kabi Oncology Limited Stable ready-to-use pharmaceutical composition of pemetrexed
CN103159633B (zh) 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 他喷他多的制备方法及用于制备他喷他多的化合物
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
CN103735500B (zh) 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
EA036258B1 (ru) 2015-03-27 2020-10-20 Грюненталь Гмбх Стабильный препарат для парентерального введения тапентадола

Also Published As

Publication number Publication date
CN103501773A (zh) 2014-01-08
EA035750B1 (ru) 2020-08-05
US20200054584A1 (en) 2020-02-20
KR20190017056A (ko) 2019-02-19
US20160220516A1 (en) 2016-08-04
ES2756776T3 (es) 2020-04-27
EP3287123A1 (en) 2018-02-28
HUE046557T2 (hu) 2020-03-30
CY1123023T1 (el) 2021-10-29
MX351584B (es) 2017-10-20
JP2017061521A (ja) 2017-03-30
JP6046057B2 (ja) 2016-12-14
PL2680832T3 (pl) 2020-03-31
EP2680832B1 (en) 2019-09-04
CA2828631C (en) 2019-10-15
US20130022670A1 (en) 2013-01-24
WO2012119727A1 (en) 2012-09-13
KR101946790B1 (ko) 2019-02-13
LT3287123T (lt) 2020-06-10
IL254854A0 (en) 2017-12-31
EA027290B1 (ru) 2017-07-31
CN107308108A (zh) 2017-11-03
KR20140017586A (ko) 2014-02-11
PT3287123T (pt) 2020-05-22
US11547678B2 (en) 2023-01-10
EA201692443A1 (ru) 2017-08-31
ZA201306478B (en) 2014-05-28
IL254854B (en) 2022-03-01
EA201300989A1 (ru) 2014-02-28
SI2680832T1 (sl) 2019-11-29
JP2014506899A (ja) 2014-03-20
AU2012224952C1 (en) 2017-03-09
SI3287123T1 (sl) 2020-07-31
IL227824A0 (en) 2013-09-30
AU2012224952A1 (en) 2013-09-19
BR112013022495A2 (pt) 2016-12-06
JP6735790B2 (ja) 2020-08-05
RS59491B1 (sr) 2019-12-31
AU2016273858B2 (en) 2018-04-26
AU2016273858A1 (en) 2017-01-12
MX369121B (es) 2019-10-30
RS60267B1 (sr) 2020-06-30
KR102051800B1 (ko) 2019-12-04
CY1125100T1 (el) 2022-07-22
PT2680832T (pt) 2019-10-28
AU2012224952B2 (en) 2016-09-22
HRP20200898T1 (hr) 2020-10-02
JP6437984B2 (ja) 2018-12-12
DK2680832T3 (da) 2019-10-14
MX2013010101A (es) 2013-10-01
PL3287123T3 (pl) 2020-11-02
EP3287123B1 (en) 2020-04-22
CA2828631A1 (en) 2012-09-13
LT2680832T (lt) 2019-10-25
DK3287123T3 (da) 2020-06-02
JP2018162271A (ja) 2018-10-18
EP3685827A1 (en) 2020-07-29
HRP20191777T1 (hr) 2020-01-24
IL227824B (en) 2018-04-30
EP2680832A1 (en) 2014-01-08
EP3597182A1 (en) 2020-01-22

Similar Documents

Publication Publication Date Title
MX388963B (es) Formulacion farmaceutica acuosa de tapentadol para administracion oral
MX2013001677A (es) Formulaciones estables de linaclotida.
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
UA106636C2 (uk) Морфолінотіазоли як позитивні алостеричні модулятори альфа 7
TN2012000392A1 (en) Oral formulations and lipophilic salts of methylnaltrexone
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
EA033171B1 (ru) Полутвёрдая фармацевтическая композиция на водной основе, содержащая тапентадол
CY1115556T1 (el) Φαρμακευτικη συνθεση για χορηγηση απο το στομα η οποια περιλαμβανει ετεξιλικη δαβιγατρανη
MX347105B (es) Composiciones farmaceuticas que comprenden hidromorfona y naloxona.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
PH12015500823A1 (en) Modified release formulations for oprozomib
MX2016001422A (es) Composicion farmaceutica de fingolimod.
MX2014014579A (es) Composiciones farmaceuticas topicas de tipo emulsion aceite en agua que contienen un retinoide.
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
EA201590732A1 (ru) Диспергируемая таблетка
EA201500366A1 (ru) Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора
WO2012108794A3 (ru) Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии
GR1007907B (el) Φαρμακευτικο σκευασμα περιεχον ενα φαινοκαρβαμικο αναστολεα της ακετυλχοληνεστερασης
MX366763B (es) Composiciones farmacéuticas de montelukast y levocetirizina.
IN2013MU01330A (es)
IN2014MU01179A (es)
WO2014141298A3 (en) Stable pharmaceutical composition of fingolimod
UA110792C2 (uk) Лікарська форма бендамустину для перорального застосування